新发1型糖尿病儿童血液中高水平的循环免疫检查点分子与发生额外自身免疫性疾病的风险相关
研究纳入143例新发1型糖尿病儿童和75例健康儿童,检测14种循环免疫检查点分子(ICM)水平,并按糖尿病发病后5年内是否发生额外自身免疫病分组。结果显示,糖尿病患儿ICM水平显著高于健康儿童,且发生第二自身免疫病者(T1D-AAD+)高于未发生者(T1D-AAD-);Cox回归显示,诊断时高水平的CD137/4-1BB和PD-1与发生额外自身免疫病的风险相关,并在60例独立队列中验证。
要点
- 新发1型糖尿病儿童循环ICM水平显著高于健康儿童。
- 发生第二自身免疫病者(T1D-AAD+)循环ICM水平高于未发生者(T1D-AAD-)。
- 诊断时高CD137/4-1BB和PD-1水平与发生额外自身免疫病风险相关。
核心结论
- 研究提示,可溶性CD137/4-1BB和PD-1分子或可作为1型糖尿病儿童的预后生物标志物,并可能为糖尿病发病时的新型免疫筛查铺路,有助于早期识别日后发生其他自身免疫病风险较高的儿童。
研究设计与样本
- 研究纳入143例无额外自身免疫病生物学和/或临床征象的新发1型糖尿病儿童和75例健康儿童,检测14种循环ICM水平。
- 根据糖尿病发病后5年内是否发生额外自身免疫病,将1型糖尿病儿童分为两组。
- 在60例新发1型糖尿病儿童组成的独立队列中验证循环ICM水平。
主要发现
- 新发糖尿病儿童循环ICM水平显著高于健康儿童。
- 发生第二自身免疫病者(T1D-AAD+)可溶性ICM水平高于未发生者(T1D-AAD-)。
- Cox回归模型显示,两个1型糖尿病队列中,诊断时高循环水平的CD137/4-1BB和PD-1分子均与发生额外自身免疫病的风险相关。
关键数值与推荐
- 检测14种循环ICM。
- 1型糖尿病儿童143例,健康儿童75例。
- 验证队列为60例新发1型糖尿病儿童。
- 随访时间为糖尿病发病后5年。
临床怎么用
- 作者认为,可溶性CD137/4-1BB和PD-1分子或可作为1型糖尿病儿童的预后生物标志物,并可能为糖尿病发病时的新型免疫筛查铺路,有助于早期识别日后发生其他自身免疫病风险较高的儿童。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We assessed the levels of blood circulating immune checkpoint molecules (ICMs) at diagnosis of type 1 diabetes, and determined their association with the risk of developing an additional autoimmune disorder over time. METHODS: Children with new-onset type 1 diabetes (n = 143), without biological and/or clinical signs of additional autoimmune disorders, and healthy children (n = 75) were enrolled, and blood circulating levels of 14 ICMs were measured. The children with type 1 diabetes were divided into two groups on the basis of the development of an additional autoimmune disease in the 5 years after diabetes onset. Differences in soluble ICM levels between the groups were assessed, and a Cox regression analysis was used to evaluate their association with the risk of development of an additional autoimmune disease over time. To validate the data, circulating ICMs were measured in an independent cohort of 60 children with new-onset type 1 diabetes stratified into two groups. RESULTS: We found that the levels of circulating ICMs were significantly higher in children with new-onset diabetes compared with healthy children. Further, we observed that children with type 1 diabetes who developed a second autoimmune disease over time (T1D-AAD+ children) had higher levels of soluble ICMs than children with type 1 diabetes who did not (T1D-AAD- children). Cox regression models revealed that high circulating levels of CD137/4-1BB and PD-1 molecules at diabetes diagnosis were associated with the risk of developing an additional autoimmune disease in both type 1 diabetes cohorts. CONCLUSIONS/INTERPRETATION: Our findings suggest that soluble CD137/4-1BB and PD-1 molecules may be used as prognostic biomarkers in children with type 1 diabetes, and may pave the way for novel immunological screening at diabetes onset, allowing early identification of children at higher risk of developing other autoimmune conditions over time.
引用
- Bruzzaniti S, Piemonte E, Mozzillo E, et al. High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease. Diabetologia. 2022. PMID: 35610521. doi:10.1007/s00125-022-05724-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。